!["[Serplulimab], the world’s first anti-PD-1 monoclonal antibody (mAb) treatment for extensive-stage small cell lung canc...](https://img5.engineering10.com/825/288/147538708252887.jpg)
03/30/2023
"[Serplulimab], the world’s first anti-PD-1 monoclonal antibody (mAb) treatment for extensive-stage small cell lung cancer (ES-SCLC), enhanced survival rates compared to chemotherapy, and is projected to be the leading immunotherapy for the disease in the next five years."
Read More: https://www.europeanpharmaceuticalreview.com/news/174766/serplulimab-increases-survival-in-small-cell-lung-cancer-patients/
